REG - IXICO plc - Huntington’s disease contract update

IXICOAnnouncement

20/01/2022 07:05

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20220120:nRST0298Za&default-theme=true

RNS Number : 0298Z  IXICO plc  20 January 2022

IXICO plc

("IXICO" or the "Company")

 

Huntington's disease contract update

 

IXICO plc (AIM: IXI), the data analytics company delivering insights in
neuroscience, announces a further update to the Huntington's disease Phase III
contract.

 

As previously announced on 23 March 2021
(https://www.londonstockexchange.com/news-article/IXI/huntington-s-disease-phase-iii-contract-updates/14910928)
, the client decided to stop dosing participants in its Phase III trial in
Huntington's disease following a pre-planned review of the data.  In April
2021
(https://www.londonstockexchange.com/news-article/IXI/trading-update/14950390)
, it was announced that the client had agreed a revised protocol for these
trials which provided for IXICO's safety and data analysis services to
continue to be utilised to support further understanding of the trialled drug
candidate data in an open-label extension.

 

The client has now confirmed that it will close its open-label extension study
in Huntington's disease in May 2022 which is expected to result in a reduction
in 2022 revenues of £0.3 million. This means that, including the loss of
expected revenues for the remaining 3-year period of the contract, the Company
now has an order book totalling £12.6 million.

 

The Company continues to have a strong pipeline of opportunities including
with this client which is now in the early stages of designing a new Phase II
clinical trial to explore different doses of the investigative drug in its
ongoing efforts to identify a disease modifying treatment for Huntingdon's
disease.

 

This announcement contains inside information for the purposes of Article 7 of
Regulation (EU) No 596/2014 (MAR)

 

For further information please contact:

 

 IXICO plc                                               +44 (0)20 3763 7498
 Giulio Cerroni, Chief Executive Officer

 Grant Nash, Chief Financial Officer

 Cenkos Securities PLC (Nominated adviser and sole broker)                +44 (0)20 7397 8900
 Giles Balleny / Max Gould (Corporate Finance)
 Michael F Johnson / Russell Kerr (Sales)

 Walbrook PR Ltd    Tel: 020 7933 8780 or IXICO@walbrookpr.com
 Paul McManus / Lianne Cawthorne /     Mob: 07980 541 893 / 07584 391 303 /
 Alice Woodings                        07407 804 654

 

About IXICO

IXICO is dedicated to delivering insights in neuroscience. Our mission is to
transform the progression of our biopharmaceutical clients' neurological
therapeutic pipelines through the application of novel imaging and digital
biomarkers.

 

IXICO's data analytics services are used by the global biopharmaceutical
industry to interpret data from brain scans and digital biosensors to enable
better trial design, site qualification, patient selection and clinical
outcomes. We provide technology-enabled services across all phases of clinical
evaluation. Our integrated digital platform provides a scalable and secure
infrastructure for the capture and analysis of regulatory compliant clinical
data to enable clients to make rapid, better informed decisions. IXICO is also
collaborating with partners to develop new analytical techniques and companion
digital health products targeted at improving patient outcomes.

 

More information is available on www.IXICO.com (http://www.IXICO.com)

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  UPDGZGZMGGFGZZG